Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV): a Phase IIb Randomized Clinical Trial
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Atorvastatin (Primary) ; Lopinavir/ritonavir (Primary) ; Telmisartan (Primary)
- Indications COVID-19 respiratory infection; Inflammation; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms ICOV; INTENSE-COV
- 30 Nov 2020 Planned End Date changed from 20 Dec 2020 to 26 Mar 2021.
- 30 Nov 2020 Planned primary completion date changed from 20 Nov 2020 to 26 Mar 2021.
- 30 Nov 2020 Status changed from not yet recruiting to recruiting.